drugset / Press release
Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder
2012-06-08 · Novo Nordisk A/S · original novonordisk.com ↗
Degludec
Insulin · regulatory
Insulin degludec/insulin aspart
Insulin degludec/insulin aspart
insulin aspart
insulin degludec
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
regular insulin
Novo Nordisk har i dag meddelt, at de amerikanske sundhedsmyndigheder (FDA) har forlænget registreringssprocessen for den ultralangtidsvirkende insulin degludec og insulin degludec/insulin aspart til behandling af type 1- og type 2-diabetes. Yderligere information: Medier: Investorer: Anne Margrethe Hauge Kasper Roseeuw Poulsen Tlf. 4442 3450 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tlf. 4442 0604 [email protected] Lars Borup Jacobsen Tlf. 3075 3479 [email protected] Selskabsmeddelelse nr. 37 / 2012
The release as fetched from its publisher. novonordisk.com ↗